Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lignocaine Microneedle vs EMLA for Venepuncture Pain
NCT05694858Phase 2
Key facts
- Status
- Recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- Hospital Canselor Tuanku Muhriz
- Modality
- Small Molecules
- Drugs
- lidocaine
- Conditions
- procedural pain
01
Overview
Phase 2, randomised, triple-blind trial of lidocaine in procedural pain (2 arms), sponsored by Hospital Canselor Tuanku Muhriz. Primary endpoints: Visual Analogue Scale Pain Score and Skin Conductance Algesimeter Index. Started Feb 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedTriple-blind
Lignocaine Microneedle
12.5mg lignocaine-embedded microneedle patch
EMLA Patch
Standard 5% EMLA patch (12.5mg lignocaine + 12.5mg prilocaine)
03
Who it enrols
Adult patients (18+) requiring venepuncture before ophthalmological procedures. Excludes patients with allergy to lignocaine/materials, recent analgesic use (<24h), hepatic impairment, psychiatric conditions, or use of CYP450 inducers/inhibitors.
04
Endpoints
Primary
Visual Analogue Scale Pain Score
Skin Conductance Algesimeter Index
Secondary
Area Under the Curve
Maximum Plasma Concentration
Beyond the preview
Go deeper on NCT05694858.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694858.